Compare YALA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YALA | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2021 |
| Metric | YALA | XERS |
|---|---|---|
| Price | $6.01 | $6.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 242.1K | ★ 1.6M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $16.40 | $34.37 |
| Revenue Next Year | $7.13 | $22.86 |
| P/E Ratio | ★ $8.76 | $590.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $5.96 | $4.30 |
| 52 Week High | $9.29 | $10.08 |
| Indicator | YALA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 32.28 | 50.83 |
| Support Level | $5.96 | $5.79 |
| Resistance Level | $7.27 | $6.41 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 4.09 | 31.49 |
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.